ABSTRACT
The article presents the results of the examination and treatment of 60 women with chronic cystitis aged 20 to 80 years. The mean disease duration was 4,9 years (ranged from 6 months to 40 years). Immunomodulator Tilorone was included in the complex therapy of 30 patients of the main group. Besides the standard examination, immunological studies, including the definition of netrophil phagocytic rates in the patients were performed. It was revealed that the inclusion of immunomodulator in the treatment regimen of exacerbations of chronic cystitis contributes to an increase of index of activation of neutrophil phagocytic reserve, significant reduction in the frequency of exacerbations of the disease after the basic and preventive courses of treatment.
Subject(s)
Cystitis, Interstitial/therapy , Interferon Inducers/administration & dosage , Tilorone/administration & dosage , Adult , Aged , Aged, 80 and over , Cystitis, Interstitial/immunology , Cystitis, Interstitial/pathology , Female , Humans , Middle Aged , Neutrophils/immunology , Neutrophils/pathology , Phagocytosis/drug effects , Phagocytosis/immunologyABSTRACT
AIM: The study of effectiveness of intravenous immunoglobulin (IVIG) in therapy of idiopathic thrombocytopenic purpura (ITP) in adults. MATERIALS AND METHODS: High doses of IVIG (0.2-0.4 g/kg b.w. for 4-6 days) were given to 6 female patients aged 20 to 59 years (median--39 years) with immune thrombocytopenia. 4 patients had primary ITP resistant to glucocorticosteroids (GCS) and 1 female had chronic ITP treated by splenectomy without effect. 1 patient with rheumatoid arthritis developed severe thrombocytopenia combined with agranulocytosis when treated with nonsteroid antiinflammatory drugs. RESULTS: The response was observed in 5 of 6 patients (in 4 patients resistant to GCS and 1 RA patient). In 3 of them the effect was rated as excellent (platelets level > 150,000 per cubic millimeter), in 2 patients it was good (platelets count from 50,000 to 150,000 per cubic millimeter). Splenectomy was performed in 4 cases with ITP on day 8-14 after IVIG therapy. The 2- and 6-month follow-up evidenced for good results of the surgical treatment. The RA patient showed a stable rise of the blood count. Serious side effects of IVIG therapy were not registered. CONCLUSION: IVIG of Russian produce is effective in the treatment of drug-induced thrombocytopenia and ITP resistant to GCS.
Subject(s)
Immunoglobulins, Intravenous/therapeutic use , Purpura, Thrombocytopenic, Idiopathic/therapy , Adult , Female , Follow-Up Studies , Humans , Middle Aged , Platelet Count/drug effects , Purpura, Thrombocytopenic, Idiopathic/blood , Russia , Splenectomy , Treatment OutcomeABSTRACT
A study was made of the relationship between hormonal (ACTH, cortisol, TSH, T3, T4, STH) and immune (E-RFC, EAC-RFC, and immunoglobulins) shifts in the time course of therapy in 106 patients with autoimmune thrombocytic purpura. A significant decrease in the level of T3 and its direct correlation with E-RFC in exacerbation of disease combined with an increase in the levels of cortisol and IgM were revealed. The treatment with glucocorticoids and immunosuppressants resulted in a more noticeable decrease in the levels of T3 and E-RCF. In case of development of hematological remission splenectomy resulted in the normalization of these shifts. In splenectomized patients with immunosuppressive therapy-refractory recurrences there was again a decrease in the level of T3 whereas the level of E-RCF was even on an increase.
